Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267746 · ClinicalTrials.gov registry record · Phase 3
A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 893
- Enrollment target
NCT02267746 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 893 participants.
The verdict
NCT02267746, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 893 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and therapeutic equivalence of a generic tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the treatment of acne vulgaris.
Interventions
- DRUG Vehicle foam
- DRUG Tazarotene (Fabior™)
- DRUG Tazarotene (Actavis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 893 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02267746
The ClinicalTrials.gov registry entry for NCT02267746 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 893 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle foam is the first listed.
NCT02267746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02267746 about?
NCT02267746 is a clinical study titled "A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris". The purpose of this study is to compare the safety and therapeutic equivalence of a generic tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the treatment of acne vulgaris.
What is the current status of trial NCT02267746?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 893 participants. The study started on 2014-06. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02267746?
The interventions under investigation include: Vehicle foam (DRUG), Tazarotene (Fabior™) (DRUG), Tazarotene (Actavis) (DRUG).
Who is sponsoring clinical trial NCT02267746?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.